JP2022540333A5 - - Google Patents

Info

Publication number
JP2022540333A5
JP2022540333A5 JP2021576580A JP2021576580A JP2022540333A5 JP 2022540333 A5 JP2022540333 A5 JP 2022540333A5 JP 2021576580 A JP2021576580 A JP 2021576580A JP 2021576580 A JP2021576580 A JP 2021576580A JP 2022540333 A5 JP2022540333 A5 JP 2022540333A5
Authority
JP
Japan
Prior art keywords
alkylene
unsubstituted
substituted
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021576580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540333A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041175 external-priority patent/WO2021007307A1/en
Publication of JP2022540333A publication Critical patent/JP2022540333A/ja
Publication of JP2022540333A5 publication Critical patent/JP2022540333A5/ja
Ceased legal-status Critical Current

Links

JP2021576580A 2019-07-10 2020-07-08 Bcl-2タンパク質阻害剤 Ceased JP2022540333A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872593P 2019-07-10 2019-07-10
US62/872,593 2019-07-10
PCT/US2020/041175 WO2021007307A1 (en) 2019-07-10 2020-07-08 Bcl-2 protein inhibitors

Publications (2)

Publication Number Publication Date
JP2022540333A JP2022540333A (ja) 2022-09-15
JP2022540333A5 true JP2022540333A5 (enExample) 2023-07-12

Family

ID=74114258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576580A Ceased JP2022540333A (ja) 2019-07-10 2020-07-08 Bcl-2タンパク質阻害剤

Country Status (12)

Country Link
US (1) US20220265834A1 (enExample)
EP (1) EP3972966A4 (enExample)
JP (1) JP2022540333A (enExample)
KR (1) KR20220034805A (enExample)
CN (1) CN114144411A (enExample)
AR (1) AR119379A1 (enExample)
AU (1) AU2020310147A1 (enExample)
CA (1) CA3140085A1 (enExample)
IL (1) IL289622A (enExample)
MX (1) MX2022000310A (enExample)
TW (1) TW202116758A (enExample)
WO (1) WO2021007307A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021167987A1 (en) * 2020-02-21 2021-08-26 Recurium Ip Holdings, Llc Difluoromethyl iodo compounds and methods
US20230167105A1 (en) * 2020-04-28 2023-06-01 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
WO2023215449A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
EP4519259A1 (en) 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
EP4519260A1 (en) 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xdegraders
TW202527930A (zh) 2023-11-07 2025-07-16 美商樹線生物科學公司 四氫異喹啉異雙功能bcl-xl降解劑
TW202535872A (zh) 2023-11-07 2025-09-16 美商樹線生物科學公司 四氫異喹啉異雙功能bcl-xl降解劑
WO2025101575A1 (en) 2023-11-07 2025-05-15 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
CN118908940B (zh) * 2024-10-11 2024-12-31 齐鲁理工学院 一种靶向抗凋亡Bcl-2的蛋白水解靶向嵌合体的制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
KR20200108301A (ko) * 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
ES3041854T3 (en) * 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
US20230167105A1 (en) * 2020-04-28 2023-06-01 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors

Similar Documents

Publication Publication Date Title
JP2022540333A5 (enExample)
CN111377871B (zh) 一种fak抑制剂及其联合用药物
ES2390606T3 (es) Inhibidores de proteasomas
CN116096372A (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
RU2020102453A (ru) Фармацевтические композиции
ES2760462T3 (es) Tratamiento dirigido del leiomiosarcoma
JP7304128B2 (ja) 白金耐性の克服における使用のためのテキサフィリン-白金(iv)コンジュゲート及び組成物
JP2009530392A5 (enExample)
JP2013538213A5 (enExample)
JP2019534865A5 (enExample)
WO2024212430A1 (zh) 一种新型紫杉烷类化合物的制备方法、应用
CN108250250B (zh) 含1,1,1-三苯基-n-(1-(吡啶-2-)亚甲基)甲胺的配合物及制备方法、应用
JP6104287B2 (ja) 四環系アントラキノン誘導体
JP2016532714A5 (enExample)
TW483897B (en) New bis-platinum complexes with polyamine ligands as antitumor agents
MXPA05000314A (es) Complejos de rutenio anticancer.
WO2023078426A1 (zh) 一种化合物、包含其的药物组合物及其应用
JP2005501121A5 (enExample)
JP2005531563A5 (enExample)
WO2018196812A1 (zh) 硼酸和硼酸酯类化合物及其制备方法和用途
Zhang et al. Synthesis and biological evaluation of novel dinuclear platinum (II) complexes derived from a novel chiral ligand
JP2010500971A5 (enExample)
CN110393714B (zh) 一种抗肿瘤药物、合成方法及应用
CN103145762B (zh) 含有芳基位阻基团的二价铂配合物、制备方法及其应用
CN102898449B (zh) 一种合成克里唑替尼中间体的方法